-
公开(公告)号：US20190046512A1
公开(公告)日：2019-02-14
申请号：US16079802
申请日：2016-12-02
Applicant: Sung Eun CHOE , Bin WU , Agios Pharmaceuticals, Inc. , Celgene Corporation
Inventor： Michael Amatangelo , Xiaolan Hu , Anjan Thakurta , Sung Eun Choe , Bin Wu
IPC: A61K31/444 , A61K45/06 , A61P35/02
Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH1 mutation or IDH2 mutation.
-
公开(公告)号：US20250017941A1
公开(公告)日：2025-01-16
申请号：US18901764
申请日：2024-09-30
Applicant: Celgene Corporation , Bristol-Myers Squibb Company
Inventor： Tonia J. Buchholz , Michael Pourdehnad , Poliana Alves Patah , Fan Wu
IPC: A61K31/5377 , A61K45/06
Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.
-
公开(公告)号：US20240400548A1
公开(公告)日：2024-12-05
申请号：US18799483
申请日：2024-08-09
Applicant: Celgene Corporation
Inventor： Maria Soraya Carrancio Anton , Tonia J. Buchholz , Antonia Lopez-Girona , Rama Krishna Narla , Michael Pourdehnad
IPC: C07D413/14 , A61K9/00 , A61P35/00 , C07K16/28
Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.
-
4.发明申请
公开(公告)号：US20240376048A1
公开(公告)日：2024-11-14
申请号：US18714760
申请日：2022-12-07
Applicant: Celgene Corporation
Inventor： Jean-Francois Brazeau , Rulin Ma , Jeffrey M. Schkeryantz , Karin Worm , Patrick W. Papa
IPC: C07D205/04 , A61K31/397 , A61K31/401 , A61K31/403 , A61K31/451 , C07D205/12 , C07D207/06 , C07D209/02 , C07D211/32
Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases. Formula (I).
-
公开(公告)号：US20240374591A1
公开(公告)日：2024-11-14
申请号：US18573752
申请日：2022-06-24
Applicant: CELGENE CORPORATION
Inventor： Matthew D. ALEXANDER , Matthew D. CORREA , Deepak DALVIE , Virginia Heather Sharron GRANT , Joshua HANSEN , Roy L. HARRIS, III , Evan J. HORN , Dehua HUANG , Christopher MAYNE , Stephen NORRIS , Veronique PLANTEVIN-KRENITSKY , John J. SAPIENZA , Lida TEHRANI , Brandon W. WHITEFIELD
IPC: A61K31/506 , A61K31/4545 , A61K31/496 , A61P35/00 , C07D401/14
Abstract: Provided herein are piperidine dione compounds having the following structure: (I) wherein Y, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
-
6.发明申请
公开(公告)号：US20240366593A1
公开(公告)日：2024-11-07
申请号：US18753467
申请日：2024-06-25
Applicant: Celgene Corporation
Inventor： Daniel W. Pierce , Lilly L. Wong
IPC: A61K31/496 , A61K45/06 , A61P35/02 , C07K16/28
Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
-
公开(公告)号：US20240350509A1
公开(公告)日：2024-10-24
申请号：US18763262
申请日：2024-07-03
Applicant: Celgene Corporation
Inventor： Benjamin M. Cohen , John F. Traverse , Jean Xu , Ying Li
IPC: A61K31/5377 , A61K31/4035 , A61K31/4412 , C07D401/04
CPC classification number: A61K31/5377 , C07D401/04 , A61K31/4035 , A61K31/4412
Abstract: Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
-
公开(公告)号：US12103920B2
公开(公告)日：2024-10-01
申请号：US18122496
申请日：2023-03-16
Applicant: Celgene Corporation
Inventor： Matthew D. Alexander , Matthew D. Correa , Deepak Dalvie , Virginia Heather Sharron Grant , Joshua Hansen , Roy L. Harris, III , Evan J. Horn , Dehua Huang , Christopher Mayne , Stephen Norris , Veronique Plantevin-Krenitsky , John J. Sapienza , Lida Tehrani , Brandon W. Whitefield
IPC: C07D401/14 , A61P35/00
CPC classification number: C07D401/14 , A61P35/00
Abstract: Provided herein are piperidine dione compounds having the following structure:
wherein RN, R1, R2, R3, R4, RN, L, V, X, a, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
-
公开(公告)号：US12064427B2
公开(公告)日：2024-08-20
申请号：US18240076
申请日：2023-08-30
Applicant: Celgene Corporation
Inventor： Anjali Agrawal , Ming J. Chen , Shyam Babu Karki , Prajwal Gunwanth Thool , Dora Visky , Ruimin Xie
IPC: A61K31/496 , A61K47/02 , A61K47/26 , A61K47/36
CPC classification number: A61K31/496 , A61K47/02 , A61K47/26 , A61K47/36
Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.
-
10.发明授权
公开(公告)号：US12053466B2
公开(公告)日：2024-08-06
申请号：US17820534
申请日：2022-08-17
Applicant: Celgene Corporation
Inventor： Daniel W. Pierce , Lilly L. Wong
IPC: A61K31/496 , A61P35/02 , C07K16/28 , A61K45/06
CPC classification number: A61K31/496 , A61P35/02 , C07K16/2809 , C07K16/2878 , A61K45/06
Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
